Skip to main content

Natalie Katz

Assistant Professor of Pediatrics
Pediatrics, Neurology

Overview


Dr. Natalie Katz is currently an Assistant Professor in the Department of Pediatrics, Division of Neurology at Duke University where she co-directs the Duke Children’s Neuromuscular Program. Her team offers multidisciplinary care to children with pediatric neuromuscular diseases. She is actively involved in clinical research and multiple clinical trials with the hopes of bringing novel therapeutic treatments to children with all types of neuromuscular disease. Dr. Katz received her MD/PhD at the University of Kansas School of Medicine, and completed residency training in Child Neurology at Children’s Mercy Hospital in Kansas City, MO. She then completed a 1-year clinical neuromuscular fellowship, along with a concurrent 2-year advanced certificate program in Experimental Therapeutics at the University of Rochester in Rochester, NY. Her personal research interests are focused on characterizing children with facioscapulohumeral muscular dystrophy (FSHD) in preparation for future clinical trials in this patient population. Additional research interests include Duchenne Muscular Dystrophy (DMD), spinal muscular atrophy (SMA), limb-girdle muscular dystrophy, Charcot-Marie-Tooth (CMT), and other rare forms of neuromuscular disease.

Current Appointments & Affiliations


Assistant Professor of Pediatrics · 2023 - Present Pediatrics, Neurology, Pediatrics

Recent Publications


Predictors of respiratory decline in neuromuscular disorders.

Journal Article Respir Med · January 2026 Neuromuscular diseases (NMDs) constitute a heterogeneous group of genetic and acquired disorders that lead to progressive muscle weakness. When the respiratory muscles are involved, impaired ventilation and ineffective airway clearance become a major sourc ... Full text Link to item Cite

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.

Journal Article Neuromuscul Disord · September 2025 Gene transfer therapy represents a major advancement in the treatment of patients with Duchenne muscular dystrophy (DMD). As clinical use expands, there is an urgent need for standardized, evidence and practice-informed guidelines to ensure safe and equita ... Full text Link to item Cite

Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years.

Journal Article J Physiol · October 2024 Duchenne muscular dystrophy (DMD) results in a progressive loss of functional skeletal muscle mass (MM) and replacement with fibrofatty tissue. Accurate evaluation of MM in DMD patients has not previously been available. Our objective was to measure MM usi ... Full text Link to item Cite
View All Publications

Recent Grants


MOVE+ Peds (Fixed rate)

ResearchPrincipal Investigator · Awarded by University of Kansas · 2025 - 2029

MOVE+ Peds (Cost reimbursement)

ResearchPrincipal Investigator · Awarded by University of Kansas · 2025 - 2029

View All Grants

Education, Training & Certifications


University of Kansas, School of Medicine · 2016 M.D.